Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"CancerVAX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CancerVax Files Non-Provisional Patent for Universal Cancer Vaccine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"CancerVAX","sponsor":"UCLA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CancerVAX Reports Positive Progress on Kids Cancer Immunotherapy Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"CancerVAX","sponsor":"StartEngine","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"CancerVAX Launches $10 Million Funding Round","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"CancerVAX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CancerVAX Expands Development Pipeline to Include a Universal CAR-T Cell Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"CancerVAX","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"CancerVax Launches $5 Million Funding Round","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"}]

    Find Clinical Drug Pipeline Developments & Deals by CancerVAX

    Menu

    CancerVAX

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              CancerVAX

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CancerVax Launches $5 Million Funding Round

              Details:

              The funding will support CancerVax to focus on the development of a discovery-stage product for single-disease cancer treatments targeting Ewing sarcoma, a rare but deadly bone and soft tissue cancer primarily affecting children and young adults.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Vaccine

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: $5.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering April 03, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              CancerVAX

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CancerVAX Expands Development Pipeline to Include a Universal CAR-T Cell Platform

              Details:

              Universal CAR-T Cell Platform – A novel and customizable low-cost treatment, to be delivered as a shot, that can reprogram natural immune T-cells inside the body to seek and destroy targeted cancer cells.

              Lead Product(s): CAR-T Cell Therapy

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 12, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              CancerVAX

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CancerVAX Launches $10 Million Funding Round

              Details:

              The net proceeds from the offering will be used to fund the further development of novel cancer vaccines leveraging the body’s immune system to destroy cancer cells.

              Lead Product(s): Cancer Vaccine

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Vaccine

              Partner/Sponsor/Collaborator: StartEngine

              Deal Size: $10.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering June 14, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              CancerVAX

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CancerVAX Reports Positive Progress on Kids Cancer Immunotherapy Treatment

              Details:

              CAR-T cells and bispecific antibodies targeting this protein biomarker. The findings of this work will create and evaluate new promising tools for recruiting and activating the patient’s own immune system to track and destroy Ewing sarcoma tumors.

              Lead Product(s): Antibody,CAR T Cell Therapy

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Large molecule

              Partner/Sponsor/Collaborator: UCLA

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 12, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              CancerVAX

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CancerVax Files Non-Provisional Patent for Universal Cancer Vaccine

              Details:

              A non-provisional patent application has been filed to protect its invention which leverages cutting-edge bioengineering techniques such as CRISPR and mRNA to develop a breakthrough universal cancer vaccine, that will use the body’s immune system to fight cancer.

              Lead Product(s): mRNA-based Vaccine

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 16, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY